Financial reports
10-Q
2024 Q2
Quarterly report
13 Feb 24
10-Q
2024 Q1
Quarterly report
13 Nov 23
10-K
2023 FY
Annual report
21 Sep 23
10-Q
2023 Q3
Quarterly report
15 May 23
10-Q
2023 Q2
Quarterly report
13 Feb 23
10-Q
2023 Q1
Quarterly report
10 Nov 22
10-K
2022 FY
Annual report
2 Sep 22
10-Q
2022 Q3
Quarterly report
16 May 22
10-Q
2022 Q2
Quarterly report
14 Feb 22
10-Q
2022 Q1
Quarterly report
15 Nov 21
Current reports
8-K
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
18 Apr 24
8-K
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
18 Apr 24
8-K
Departure of Directors or Certain Officers
8 Mar 24
8-K
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update
13 Feb 24
8-K
Departure of Directors or Certain Officers
7 Dec 23
8-K
Benitec Biopharma Announces First Subject Dosed in Phase
30 Nov 23
8-K
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update
13 Nov 23
8-K
Departure of Directors or Certain Officers
16 Oct 23
8-K
Other Events
28 Sep 23
8-K
Financial Results and Provides Operational Update
21 Sep 23
Registration and prospectus
D
$40.00 mm in equity / options / securities to be acquired, sold $40.00 mm, 17 investors
25 Apr 24
S-3
Shelf registration
23 Feb 24
S-8
Registration of securities for employees
22 Dec 23
424B4
Prospectus supplement with pricing info
10 Aug 23
S-1/A
IPO registration (amended)
7 Aug 23
S-1/A
IPO registration (amended)
3 Aug 23
S-1/A
IPO registration (amended)
31 Jul 23
S-1
IPO registration
7 Jul 23
S-1
IPO registration
12 Dec 22
424B4
Prospectus supplement with pricing info
14 Sep 22
Proxies
DEFA14A
Additional proxy soliciting materials
20 Oct 23
DEF 14A
Definitive proxy
20 Oct 23
DEFA14A
Additional proxy soliciting materials
25 Oct 22
DEF 14A
Definitive proxy
25 Oct 22
PRE 14A
Preliminary proxy
14 Oct 22
DEF 14A
Definitive proxy
22 Oct 21
PRE 14A
Preliminary proxy
12 Oct 21
DEF 14A
Definitive proxy
22 Oct 20
Other
EFFECT
Notice of effectiveness
6 Mar 24
EFFECT
Notice of effectiveness
9 Aug 23
CORRESP
Correspondence with SEC
3 Aug 23
CORRESP
Correspondence with SEC
3 Aug 23
UPLOAD
Letter from SEC
11 Jul 23
EFFECT
Notice of effectiveness
20 Dec 22
CORRESP
Correspondence with SEC
15 Dec 22
UPLOAD
Letter from SEC
14 Dec 22
EFFECT
Notice of effectiveness
13 Sep 22
CORRESP
Correspondence with SEC
8 Sep 22
Ownership
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
11 Apr 24
4
Jerel A. Banks
8 Mar 24
4
Megan Boston
8 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
14 Feb 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
SC 13G/A
FRANKLIN RESOURCES INC
11 Dec 23
4
Edward F Smith
7 Dec 23
4
Peter Francis
7 Dec 23
4
J KEVIN BUCHI
7 Dec 23